Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

Oral Bexarotene Gains Marketing Authorization for CTCL in Hong Kong

July 16th 2024

Bexarotene has been granted marketing authorization in Hong Kong for the treatment of pretreated cutaneous manifestations of cutaneous T-cell lymphoma.

Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC

July 12th 2024

Health Canada has approved osimertinib/chemotherapy for advanced non–small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.

China’s NMPA Approves Selinexor for R/R DLBCL

July 8th 2024

Selinexor has received approval as monotherapy for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in China.

European Commission Approves Osimertinib Plus Chemo for Advanced EGFR+ NSCLC

July 8th 2024

Frontline osimertinib plus chemotherapy has been approved in the European Union for adult patients with advanced EGFR-mutated non–small cell lung cancer.

Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer

July 1st 2024

The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.

TAS-102 Followed By Regorafenib Identified As Optimal Treatment Sequence in Pretreated mCRC

June 28th 2024

TAS-102 followed by regorafenib is an optimal sequence vs regorafenib followed by TAS-102 in select patients with metastatic colorectal cancer.

Epcoritamab Receives Positive CHMP Opinion for Relapsed/Refractory Follicular Lymphoma

June 28th 2024

The EMA’s CHMP has recommended a conditional marketing authorization for epcoritamab for patients with relapsed/refractory follicular lymphoma.

Erdafitinib Approaches EU Approval for FGFR3+ Unresectable or Metastatic Urothelial Carcinoma

June 28th 2024

The EMA's CHMP has adopted a positive opinion regarding erdafitinib in patients with FGFR3+ unresectable or metastatic urothelial carcinoma.

CHMP Recommends Odronextamab for Relapsed/Refractory FL and DLBCL

June 28th 2024

The EMA's CHMP has recommended the conditional marketing authorization of odronextamab for relapsed/refractory FL and DLBCL.

China’s NMPA Approves First-Line Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC

June 26th 2024

Osimertinib received approval in China in combination with pemetrexed and platinum-based chemotherapy for patients with advanced EGFR-mutant NSCLC.

First-Line Osimertinib Plus Chemo Approved in Japan for EGFR+ Advanced NSCLC

June 25th 2024

The Japanese PMDA has approved first-line osimertinib plus chemotherapy for EGFR-mutated advanced non–small cell lung cancer.

First-Line Toripalimab Plus Chemo Wins Approval in China for Advanced TNBC

June 25th 2024

China’s NMPA approved toripalimab plus nab-paclitaxel for the first-line treatment of recurrent or metastatic triple-negative breast cancer.

Momelotinib Wins Japanese Approval for Myelofibrosis

June 24th 2024

The Ministry of Health, Labour, and Welfare in Japan has approved momelotinib for use in patients with myelofibrosis.

Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer

June 24th 2024

An expanded indication for dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer is under EMA review.

Valemetostat Tosilate Approved in Japan for R/R PTCL

June 24th 2024

Valemetostat tosilate has been approved by the Japan Ministry of Health, Labor and Welfare for the treatment of patients with relapsed/refractory PTCL.

Fruquintinib Wins European Approval for Pretreated mCRC

June 24th 2024

The European Commission has approved fruquintinib for select patients with pretreated metastatic colorectal cancer.

EMA Validates Filings for Subcutaneous Formulation of Nivolumab in Solid Tumors

June 21st 2024

The EMA has validated an extension application for the subcutaneous formulation of nivolumab in adult patients with solid tumor indications.

China’s NMPA Grants Priority Review to Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

June 20th 2024

Tafasitamab plus lenalidomide has been granted priority review in China for transplant-ineligible, relapsed/refractory diffuse large B-cell lymphoma.

European Commission Approves Capivasertib Plus Fulvestrant for ER+ Breast Cancer

June 20th 2024

Capivasertib/fulvestrant was approved in the EU for pretreated, ER-positive, HER2‑negative advanced cancer with 1 or more PIK3CA, AKT1, or PTEN alterations.

Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL

June 19th 2024

Golidocitinib has received approval from China’s NMPA for relapsed/refractory peripheral T-cell lymphoma.